NRC Health Q4 TRCV rises 8% to USD 144.1 million

Reuters

Feb 03

NRC Health Q4 TRCV rises 8% to USD 144.1 million

NRC Health $(NRC)$ reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share $(EPS)$ both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value (TRCV) in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - National Research Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203161940) on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608872397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608872397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608872397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608872397","market":"nz","top_or_hot":-1,"title":"NRC Health Q4 TRCV rises 8% to USD 144.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRC Health Q4 TRCV rises 8% to USD 144.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NRC Health <a href=\"https://laohu8.com/S/NRC\">$(NRC)$</a> reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value (TRCV) in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - <a href=\"https://laohu8.com/S/NRCIA\">National Research</a> Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203161940) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRC Health Q4 TRCV rises 8% to USD 144.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRC Health Q4 TRCV rises 8% to USD 144.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRC Health Q4 TRCV rises 8% to USD 144.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NRC Health <a href=\"https://laohu8.com/S/NRC\">$(NRC)$</a> reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value (TRCV) in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - <a href=\"https://laohu8.com/S/NRCIA\">National Research</a> Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203161940) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL7M6zj5:1","article_id":"2608872397","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608872397","pubTimestamp":1770127340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NRC Health  reported its financial results for the fourth quarter  and full year  2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share  both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value  in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","NRC":"National Research Corp."},"translate_title":"NRC Health第四季度TRCV增长8%至1.441亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRC":0.9},"content_text":"NRC Health Q4 TRCV rises 8% to USD 144.1 million\n    \n\n        NRC Health $(NRC)$ reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share $(EPS)$ both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value (TRCV) in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - National Research Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203161940) on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}